Banco Santander (SAN: EUR4.41) increases after finding support; +3c [0.7%] 17 June 2024

NEWS BITES - EUROPE

www.buysellsignals.com

Banco Santander, S.A.'s (MA: SAN EUR4.41) stock price increased 0.7% after hitting the lower Bollinger Band three times in the last ten days. This is a bullish signal. The lower Bollinger Band marks the trajectory of support on a stock price.

Banco Santander's stock price increased 3.0c (0.7%) from its previous trading session to close at EUR4.41.

Compared with the IBEX 35 Index which fell 32.8 points (0.3%) in the day, the relative price increase was 1.0%.

Banco Santander, S.A. is Spain's largest Banks sector company by market cap.

There were 29,980,000 shares worth EUR132.2 million ($141.4 million) traded today. The volume was close to average trading.

BANCO SANTANDER (SAN) Stock Dashboard [traded in Euro, EUR] End-of-Day Mon, Jun 17

http://www.gruposantander.com

LastEUR4.41Market CapEUR75 billion [US$81 billion]
P/E8.2Dividend Yield % (TTM)4.1
EPS (FY2022)54.0cDPS (past 12 months)EUR0.1 or 11c
Shares Outstanding17,080,711,000ExchangeSPANISH [Madrid]
SAN in IndicesIBEX 35 [of 35 stocks]SectorBanks company [of 10 stocks]
EPS Growth (FY2022 vs FY2021)22.7%Today's VI*1.0
Today's Volume29,980,000Currency1.000 EUR = 1.069 USD
Ave Daily Volume30,224,760 sharesPV$1000 (1 yr)EUR1,510
US$1,487
52-Week Price Range2.88 - 4.93
Days Untraded in Past Month3/21; Stock is not Liquid

A year ago the exchange rate was USD 1 = 0.92 EUR. USD1000 would have bought EUR921. A year ago the Banco Santander share price was EUR3.05. EUR921 would have bought 301.7 Banco Santander shares on that day. Those 301.7 shares would be worth EUR1,330 at today's share price of EUR4.41. At today's exchange rate of USD1=0.94 EUR this is equivalent to USD1,422. Dividends reinvested are worth EUR66 ($65). PV$1000= $1,487.

Primary Exchange and Other Listings: Trading Currency and Volume (Excl ADR)

ExchangeTickerCurrencyLastADVTVol % of TotalToday's VI
MadridSANEUR4.4130,224,76098.31
XetraBSD2EUR4.3655,1231.05.5
LondonBNCGBX370.5422,1460.60.4
OTCBBBCDRFUSD4.5320,8380.12.2
Total100.00

1 EUR= 84.2744 GBX [Pence Sterling]; 1 EUR= 1.0692 USD

ADVT= Avg. Daily Volume of Trading; VI= Volume Index (1 is avg)

INDEX

SECTION 1 RECENT NEWS AND RESEARCH

SECTION 2 THE PAST YEAR: PRESS RELEASES

SECTION 3 TODAY'S BULLISH SIGNALS

SECTION 4 ONGOING BULLISH PARAMETERS

SECTION 5 TODAY'S BEARISH SIGNALS

SECTION 6 ONGOING BEARISH PARAMETERS

SECTION 7 CORPORATE PROFILE

SECTION 8 BANK METRICS

SECTION 9 DIVIDEND

SECTION 10 TOP MANAGEMENT AND BOARD OF DIRECTORS

Read more...

ANNEXURE

APPENDIX I DATA & ARCHIVE DOWNLOAD CENTER

APPENDIX II STOCK IDENTIFIERS

GLOSSARY

SECTION 1 RECENT NEWS AND RESEARCH

VI* Volume Index = Number of shares traded today/Average number of shares traded per day.

Past quarter momentum up: Banco Santander jumps 9.3% on average volume 1.0 times average.

In the past month there were 3 days untraded out of 21 trading days in the month. Days Untraded decreased from 11 days in the previous month to 3 days in the past month.

Past month to HighLowVWAPVolume Index *Days Untraded
17 Jun 20244.94.34.60.93
17 May 20244.94.34.70.511
17 Apr 20244.44.34.40.9-

[*Volume Index of 0.9 means volume for the month was 0.9 times its 12-month average]

[VWAP is defined as the Volume Weighted Average Price; High Low prices and VWAP are shown in EUR]

SECTION 2 THE PAST YEAR: PRESS RELEASES

2.1 Press Releases and Corporate Wire

Press Release article 1 of 16, Source: West Corporation, 108 words

June 12: Banco Santander Sanofi: Information concerning the total number of voting rights and shares May 2024

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Reglement general de lAutorite des Marches Financiers (Regulation of the French stock market authority)

Sanofia French societe anonyme with a registered share capital of 2,529,599,938 Registered office : 46, avenue de la Grande Armee - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under number 395030844

Source: West Corporation

Press Release article 2 of 16, Source: West Corporation, 325 words

June 03: Banco Santander Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd reduced the risk of recurrence or death by 40% versus VRd followed by Rd in the investigational use for transplant-ineligible newly diagnosed multiple myeloma patientsKey primary endpoint of progression-free survival met, demonstrating Sarclisa's potential as a first-in-class combination to address gaps in care for newly diagnosed transplant-ineligible patientsFull data simultaneously published in NEJM and formed the basis of regulatory submissions Paris, June 3, 2024. Data from the IMROZ phase 3 study demonstrated Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd (the IMROZ regimen) significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant. IMROZ is the first global phase 3 study of an anti-CD38 monoclonal antibody in combination with standard-of-care VRd to significantly improve PFS and show deep responses in this patient population who often have poor prognoses. The results were shared in an oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting and simultaneously published in the New England Journal of Medicine (NEJM).

The use of Sarclisa in combination with VRd in transplant-ineligible NDMM is investigational and has not been fully evaluated by any regulatory authority.

Thierry Facon, MDProfessor of Haematology in the Department of Haematology, Lille University Hospital, Lille, France, member of French Academy of Medicine and IMROZ Principal InvestigatorThe significant progression-free survival benefit observed with Sarclisa combination therapy compared to VRd is important and encouraging for patients with newly diagnosed multiple myeloma.

Press Release article 3 of 16, Source: West Corporation, 327 words

May 31: Banco Santander Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

Sanofi launches 2024 global Employee Stock Purchase Plan

Paris, May 31, 2024. Sanofis global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to secure that employees benefit from the company growth and success.

Paul HudsonChief Executive Officer of Sanofi This plan underscores our ongoing commitment to unite the people of Sanofi behind our long-term growth, with the opportunity to have a share in our collective company performance as we break new ground with innovative medicines and vaccines. The Board of Directors and I are proud of the continued increase in participation over the past decade, a clear reflection of our employees confidence in the transformation we are undertaking to become a modern healthcare company.

From June 4 to June 24, 2024, employees will be offered shares at a subscription price of 72.87, which is equal to a 20% discount on the average of the 20 opening prices of Sanofi shares from May 2 to May 29, 2024. For every five shares subscribed, employees will be offered one free matching share (up to a maximum of four matching shares per employee). Every eligible employee may purchase up to 1,500 Sanofi shares within the legal limit (maximum payment amount may not exceed 25% of their gross annual salary, minus any voluntary deductions already made under employee savings schemes, such as Group Savings Plan or Group Retirement Savings Plan, during 2024).

In 2023, more than 33,100 Sanofi employees (39.4%) chose to invest in the company through the program. Today, nearly 75,000 current or former Sanofi employees are shareholders, and hold approximately 2.58%1 of its capital.

Detailed conditionsAn eligibility condition of three months employment by the closing date of the offer period will apply.

Press Release article 4 of 16, Source: West Corporation, 306 words

May 31: Banco Santander Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

Paris and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). The revised target action date is September 27, 2024. The FDA did not raise any concerns regarding the approvability of Dupixent for this indication.

The FDA had requested additional efficacy analyses on the efficacy of Dupixent in the BOREAS and NOTUS pivotal trials. Based on the submission of these analyses earlier in May, the agency has now determined that this additional information constituted a major amendment to the sBLA and extended the target action date accordingly.

Sanofi and Regeneron are confident that the additional analyses strongly support the approval of Dupixent in COPD with evidence of type 2 inflammation, and are committed to working with the FDA to bring Dupixent to patients living with uncontrolled COPD as quickly as possible.

Additionally, submissions for Dupixent in COPD are currently under review with regulatory authorities around the world, including the European Union and China. Recently, the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion and recommended the approval of Dupixent as an add-on maintenance treatment in adults with uncontrolled COPD characterized by raised blood eosinophils. The potential use of Dupixent in COPD is currently under clinical development, and the safety and efficacy have not been fully evaluated by any regulatory authority.

Press Release article 5 of 16, Source: West Corporation, 328 words

May 31: Banco Santander Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

Dupixent recommended for EU approval by the CHMP to treat patients with COPD

Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decade Paris and Tarrytown, N.Y. May 31, 2024. The European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union (EU) as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. The European Commission is expected to announce a final decision on the Dupixent application in the coming months.

COPD is a respiratory disease that damages the lungs and causes progressive lung function decline and is the fourth leading cause of death worldwide. Symptoms include persistent cough, excessive mucus production and shortness of breath that may impair the ability to perform routine daily activities, which may lead to sleep disturbances, anxiety and depression. COPD is also associated with a significant health and economic burden due to recurrent acute exacerbations that require systemic corticosteroid treatment and/or lead to hospitalization. Smoking and exposure to noxious particles are key risk factors for COPD, but even individuals who quit smoking can still develop or continue having the disease. There have been no new treatment approaches approved for more than a decade.

The positive CHMP opinion is supported by data from the landmark BOREAS and NOTUS phase 3 studies that evaluated the efficacy and safety of Dupixent in adults with uncontrolled COPD with evidence of type 2 inflammation (i.e., blood eosinophils 300 cells per L).

Press Release article 6 of 16, Source: West Corporation, 289 words

May 30: Banco Santander Press Release: Sanofi completes acquisition of Inhibrx, Inc.

Sanofi completes acquisition of Inhibrx, Inc.

Paris, May 30, 2024. Sanofi announced today the completion of its acquisition of Inhibrx, Inc. (Inhibrx). The acquisition adds SAR447537 (formerly INBRX-101) to Sanofis rare disease pipeline, underscoring the companys commitment to pursuing differentiated and potential best-in-class medicines that build upon our existing strengths and capabilities.

SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue. SAR447537 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals.

The former holders of shares of Inhibrx common stock voted to approve the acquisition at a special meeting of stockholders on May 24, 2024. Upon the closing of the acquisition, former shareholders of Inhibrx became entitled to receive $30.00 per share in cash, which represents a total equity value of approximately $1.7 billion (on a fully diluted basis), as well as one contingent value right per share to receive $5.00 upon the achievement of a regulatory milestone.

Sanofi completed its acquisition of Inhibrx through the merger of an indirect, wholly owned subsidiary of Sanofi with and into Inhibrx, with Inhibrx continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi.

Prior to the closing of the acquisition, Inhibrx completed the spin-off of Inhibrx Biosciences, Inc. (Inhibrx Biosciences), distributing 92% of Inhibrx Biosciencess shares to holders of shares of Inhibrx common stock as of May 17, 2024.

Press Release article 7 of 16, Source: West Corporation, 315 words

May 27: Banco Santander Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

FDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care treatment for patients with newly diagnosed transplant-ineligible multiple myeloma Pivotal IMROZ phase 3 study results to be featured during oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Paris, May 27, 2024. The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma. The target action date for the FDA decision is September 27, 2024. A regulatory submission is also under review in the European Union (EU).

Dietmar Berger, M.D., Ph.D. Chief Medical Officer, Global Head of Development at SanofiDespite recent advancements in multiple myeloma treatment, there remains a significant unmet need for new frontline therapies, particularly for transplant-ineligible patients who can face poor outcomes from the disease. The filing acceptances, as well as the FDAs Priority Review designation, reinforce our confidence in Sarclisa as a potential best-in-class treatment and represent a critical step toward advancing this combination in a difficult-to-treat cancer.

The sBLA, as well as the submission in the EU, is based on positive results from the IMROZ phase 3 clinical study evaluating the investigational use of Sarclisa in combination with standard-of-care VRd.

Press Release article 8 of 16, Source: West Corporation, 321 words

May 21: Banco Santander Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries.

Sanofi will leverage this partnership to provide access to proprietary data to develop AI models as it continues on its path to becoming the first biopharma company powered by AI at scale.

Paul HudsonCEO, SanofiThis unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substantially powered by AI. Next generation, first-of-its kind AI model customizations will be an important foundation in our efforts to shape the future of drug development for pharma and for the many patients waiting for innovative treatments.

OpenAI, the world leader in AI technology, will contribute access to cutting-edge AI capabilities, including the ability to fine-tune models, deep AI expertise and dedicated thought partnership and resources.

Brad LightcapCOO, OpenAIThere is massive potential for AI to accelerate drug development. We are excited to collaborate with Sanofi and Formation Bio to help patients and their families by bringing new medicines to market.

Formation Bio, an AI and tech-driven drug developer with its own pipeline of drug assets, will provide extensive engineering resources, experience operating at the intersection of pharma and AI, and its tech-driven development platform to design, develop and deploy AI technologies across all aspects of the pharma lifecycle.

Benjamine LiuCo-Founder & CEO, Formation BioI firmly believe that by combining our strengths, Sanofi, OpenAI and Formation Bio can reimagine drug development in the pharma industry.

Press Release article 9 of 16, Source: West Corporation, 305 words

May 20: Banco Santander Press Release: Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils 300 cells per L). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS study, with its data presented at a late-breaking session of the 2024 American Thoracic Society (ATS) International Conference and simultaneously published in the New England Journal of Medicine (NEJM).

Surya Bhatt, M.D., MSPH Professor at the University of Alabama at Birmingham, Division of Pulmonary, Allergy, and Critical Care Medicine, and a co-principal investigator of the study In my more than 20 years of practice, there have been limited advancements for patients struggling with the debilitating effects of uncontrolled COPD, and too many patients experience a vicious cycle of exacerbations that can result in loss of lung function and greatly diminish their quality of life. In NOTUS, dupilumab reduced exacerbations by a magnitude never seen before with an investigational biologic in a phase 3 COPD clinical study.

Press Release article 10 of 16, Source: West Corporation, 109 words

May 20: Banco Santander Sanofi: Information concerning the total number of voting rights and shares - April 2024

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Reglement general de lAutorite des Marches Financiers (Regulation of the French stock market authority)

Sanofia French societe anonyme with a registered share capital of 2,529,599,938 Registered office : 46, avenue de la Grande Armee - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under number 395030844

Source: West Corporation

Press Release article 11 of 16, Source: West Corporation, 320 words

May 13: Banco Santander Press Release: Sanofi adds over1 billion for biomanufacturingto2.5 billion already committed in major projects in France to support health sovereignty

Sanofi adds over1 billion for biomanufacturingto2.5 billion already committed in major projects in France to support health sovereignty

Paris, May 13, 2024. As the largest private contributor to the security and independence of France's health ecosystem, Sanofi today announces an investment of more than 1 billion to create new bioproduction capacity at its sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime) and Lyon Gerland (Rhone). This new investment will create more than 500 jobs and significantly strengthen France's ability to control the production of essential medicines from start to finish, for the present day and into the future. This plan brings to more than 3.5 billion the amount committed by Sanofi since the Covid-19 pandemic in major projects to keep production of medicines and vaccines in France for patients around the world.

In Vitry-sur-Seine, Sanofi will invest 1 billion to build a new facility that will double the site's monoclonal antibody production capacity. Several biologics in development amongst Sanofis 12 potential blockbusters, in chronic obstructive pulmonary disorder (COPD), asthma, multiple sclerosis or type 1 diabetes, could be produced in Vitry to meet the needs of millions of patients in France and around the world. Sanofi anticipates the creation of 350 jobs as a result of this investment.At the Le Trait site in Normandy, Sanofi will invest 100 million to develop new capacity for biologics formulation, filling, device assembly and packaging. It will support the launch of future biologics and vaccines, as well as the continued growth of Dupixent, which already is indicated in several inflammatory diseases and could soon become the first biologic indicated in COPD. This investment will support 150 jobs.In Lyon Gerland, Sanofi is investing 10 million to locate the production of TZield in France.

Press Release article 12 of 16, Source: West Corporation, 283 words

May 10: Banco Santander Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Paris and Gaithersburg, Md., United States. May 10, 2024.As part of Sanofis commitment to developing a diverse portfolio of best-in-class vaccines, the company has entered into a co-exclusive licensing agreement with Novavax, a biotechnology company headquartered in Maryland, US.

Jean-Francois ToussaintGlobal Head of Vaccines R&DWith flu and COVID-19 hospital admission rates now closely mirroring each other, we have an opportunity to develop non-mRNA flu-COVID-19 combination vaccines offering patients both enhanced convenience and protection against two serious respiratory viruses. Were excited by the prospect of combining Novavaxs adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines that have demonstrated superior protection against flu and its serious complications. Improved tolerability and thermostability, without compromise on efficacy, are what regulators, recommending bodies, and patients will demand.

John JacobsCEO, Novavax

This collaboration is important for Novavax and for global public health. Our new partnership combines Novavaxs proprietary recombinant protein and nanoparticle technologies, Matrix adjuvant, and R&D expertise with Sanofis world-class leadership in launching and commercializing innovative vaccines. Together, we can broaden access to both our COVID-19 vaccine and our adjuvant to ensure more individuals can benefit from the protection vaccines can provide. Novavax is now in a stronger position to refocus our efforts on leveraging our technology platform and novel adjuvant in research and development and pipeline expansion to help advance our mission of developing life-saving vaccines to fight infectious diseases.

Press Release article 13 of 16, Source: West Corporation, 324 words

May 02: Banco Santander Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

Paris, May 2, 2024. Beyfortus reduced respiratory syncytial virus (RSV) hospitalizations by 82% (95% CI: 65.6 to 90.2) in infants under 6 months of age, compared to infants who received no RSV intervention, according to the interim results of an ongoing study published in The Lancet. These results, from the first RSV season after Beyfortus introduction, are part of the three-year NIRSE-GAL study conducted in Galicia, Spain under a collaborative framework with the Galician Directorate of Public Health of the Xunta de Galicia (Galician government) and Sanofi.1

The results echo real-world evidence (RWE) reported from several broad infant immunization programs across the US, Spain and France during the 2023-2024 RSV season, which add to the consistent and high efficacy seen in pivotal clinical studies with Beyfortus. Real-world evidence demonstrates if a treatment or immunization is effective in day-to-day practice, as opposed to efficacy determined in carefully controlled clinical trials. A favorable safety profile was observed following Beyfortus use, consistent with clinical study results.1-10

Federico Martinon TorresHead of Pediatrics, Hospital Clinico Universitario Santiago, Spain and principal investigator of NIRSE-GAL studyGalicia provides the first population-based real-world evidence of the impact of nirsevimab to prevent RSV disease in infants, showing a reduction by almost 90% in the number of hospitalizations due to this virus when compared with several previous RSV seasons. This achievement is the result of the exemplary pragmatic collaboration among scientists, industry, healthcare providers and policy makers aligned with a carefully planned roll-out of the immunization campaign, and the outstanding response of the Galician parents to this prophylaxis campaign.

Thomas TriompheExecutive Vice President, Vaccines, SanofiThe scale and speed of impact seen after Beyfortus introduction demonstrates the strength of all-infant immunization strategies against RSV in babies.

Press Release article 14 of 16, Source: West Corporation, 286 words

April 30: Banco Santander Press Release: Annual General Meeting of April 30, 2024

Annual General Meeting of April 30, 2024

Approval of the financial statements for the fiscal year 2023Distribution of a cash dividend of 3.76 per share, with payment as of May 15, 2024Board composition: renewal of two Directors and appointment of three new Independent Directors Paris, April 30, 2024. The Combined General Shareholders Meeting of Sanofi was held on April30, 2024, under the chairmanship of Frederic Oudea. All resolutions submitted to the vote were adopted by the shareholders.

The General Meeting approved the individual Company and consolidated financial statements for the fiscal year 2023 and decided on the distribution of an ordinary annual dividend of 3.76 per share. The payment of the dividend will be made on May 15, 2024.

The General Meeting also renewed Rachel Duan and Lise Kingo as Directors, and approved the appointment of Clotilde Delbos, Anne-Francoise Nesmes and John Sundy, all being qualified as independent Directors.

On the proposal of the Appointments, Governance and CSR Committee, the Board of Directors has appointed Clotilde Delbos as member of the Audit and Compensation Committees, Anne-Francoise Nesmes as member of the Audit Committee and John Sundy as member of the Scientific Committee. Antoine Yver becomes Chair of the Scientific Committee and a member of the Strategy Review Committee.

Following the General Meeting, the Board of Directors is temporarily composed of 17 Directors, including two directors representing employees. It has an independence rate of 80% and a gender diversity rate of 47%. It also has 8 directors of foreign nationality, i.e. a rate of 47 %.

The voting results and the videocast of the Annual General Meeting are available here.

Press Release article 15 of 16, Source: West Corporation, 288 words

April 25: Banco Santander Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance

Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance

Paris, April 25, 2024

Sales growth of 6.7% at CER and business EPS(1) of 1.78

Dupixent sales up 24.9% to 2,835 million, on target to deliver ~13bn in 2024Pharma launches up 90.5% to 606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performanceR&D expenses grew 11.8%, reflecting strategic shift of resources into developmentSG&A expenses grew 2.9%, less than sales growthBusiness EPS(1) of 1.78, down 17.6% reported and 7.4% at CERIFRS EPS of 0.91, down 43.1% reported R&D transformation advanced further

Three regulatory approvals: new Dupixent indications in the US and Japan and Beyfortus in JapanPositive phase 3 results for rilzabrutinib in immune thrombocytopenia, a rare diseaseReaffirming increasing pipeline news flow over 2024-2025, including 12 phase 3 data readouts Corporate Social Responsibility progress

Sanofi Global Health Unit: making a difference for patients in low- and middle-income countriesCancer and work: Sanofi supporting health and wellbeing in the workplace Business EPS guidance reiterated

Paul Hudson, Chief Executive Officer, commented:

We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. Continued strong performance by Dupixent and our new launches drove sales growth of seven percent. In parallel, we are delivering on our promise of increased investments in our late-stage pipeline to fully realize its value for patients and Sanofi.

Press Release article 16 of 16, Source: West Corporation, 358 words

April 23: Banco Santander Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITPRegulatory submissions in the US and EU anticipated by year-endRilzabrutinib is one of 12 potential medicines and vaccines in Sanofis robust immunology pipeline and a testament to Sanofis ability to successfully accelerate and build a portfolio of next-generation transformative treatments for immune diseasesIn addition to ITP, rilzabrutinib is being studied across a variety of immune-mediated diseases including asthma, chronic spontaneous urticaria, prurigo nodularis, IgG4-related disease and warm autoimmune hemolytic anemia Paris, April 23, 2024. Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP). The safety profile of rilzabrutinib was consistent with that reported in previous studies.LUNA 3 study met its primary endpoint demonstrating a significantly higher proportion of patients receiving rilzabrutinib achieved the primary endpoint of durable platelet response versus placebo. This clinically and statistically significant result was achieved in a population of patients with primary ITP that had been refractory to prior therapy. Overall, study participants had a median of four prior ITP therapies and a median baseline platelet count of 15,000/L (normal platelet count levels typically range from 150,000-450,000/L). Positive results on key secondary endpoints also underscore the potential for rilzabrutinib to deliver clinically meaningful benefits for patients living with persistent and chronic ITP.

Rilzabrutinib was granted Fast Track Designation by the US Food and Drug Administration (FDA) for the treatment of ITP in November 2020 and was previously granted Orphan Drug Designation.

Houman AshrafianExecutive Vice President, Head of Research and Development, SanofiThe results of this study reinforce rilzabrutinibs potential to be a first-in-class oral, reversible BTK inhibitor that can provide clinically meaningful improvements for people living with severe immune-mediated diseases like ITP.

SECTION 3 TODAY'S BULLISH SIGNALS

Price/Earnings:

Banco Santander stock is trading at the sixth lowest P/E multiple in the IBEX 35 Index.Banco Santander stock is the fifteenth highest dividend yielding stock in the IBEX 35 Index.

3.1 Relative Value Indicators: Undervaluation compared with Index averages and bond yield

- Earnings yield of 12.2% is more attractive compared with the Spanish average earning yield of 7%.

- The earnings yield of 12.2% is 3.7 times the 10-year bond yield of 3.3%.

(All figures in %)

Earnings Yield12.2
Spanish avg7
Dividend Yield4.1
Bond Yield3.3

Dividend Yield > Bond Yield of 3.34%:

The dividend yield of 4.1% is 1.23 times the triple-A bond yield of 3.34%. The times factor of 1.23 is above the benchmark factor of 0.67 times set by Benjamin Graham.

(All figures in %)

Dividend Yield4.1
Bond Yield3.34
Spread0.76

3.2 Rank in the top 24% by Relative Valuation in the Spanish market

DescriptionValueRank
P/E * P/NTA7.76In Top 14%
Price/Earnings8.2In Top 14%
Price to Book Value0.9In Top 24%

3.3 Rank in the top 13% by Price Performance in the Spanish market

DescriptionValueRank
PV1000 [1 yr] $1,487In Top 13%

3.4 Uptrend

Beta > 1 combined with price rise. The Beta of the stock is 1.4.

Price/Moving Average Price of 1.16:

- The Price/MAP 200 for Banco Santander is 1.16. Being higher than 1 is a bullish indicator. It is higher than the Price/MAP 200 for the IBEX 35 Index of 1.08, a second bullish indicator. The stock is trading above both its MAPs and the 50-day MAP of EUR4.38 is higher than the 200-day MAP of EUR3.79, a third bullish indicator.

Past Quarter:

- In the last three months the stock has hit a new 52-week high thirteen times, pointing to a significant uptrend.

3.5 Other Bullish Signals

- Return on Equity of 11.0% versus sector average of 9.9%.

- Over the last 3 years average annual compound growth rate of earnings per share was 17.8%. This is considered moderate.

- As per the Du Pont analysis, Return on Equity of 11.0% is better than sector average of 9.9%. This is computed as net profit margin of 20.7% times asset turnover [sales/assets] of 0.03 times leverage factor [total assets/shareholders' equity] of 17.8.

3.6 Oversold/Bullish Signals:

- The Relative Strength Index (RSI) of 26.0 has breached the oversold line of 30, suggesting the price decrease of 6% in the last 14 days is unusually high.

- The stock is oversold according to the Williams % R indicator of -81.0, suggesting the price is close to its 14-day low of EUR4.30.

- The Stochastic indicator of 11.0 has pierced the oversold line of 20; this indicates the price is close to its 14-day low and is likely to revert to an uptrend.

SECTION 4 ONGOING BULLISH PARAMETERS

4.1 Banco Santander sees dividend rise for a third consecutive year

Banco Santander reported dividends per share of 18.10c in the past year, up 53.7% from the previous year. This is the third consecutive dividend increase. In the past 3 years average annual compound growth rate of dividends was 87.4%.

4.2 Past two-years

- The shares rose 60.01c (24.2%) a year ago which accelerated to EUR1.33 (43.1%) in the past year.

- Banco Santander rose for a second consecutive year. In the previous year the shares rose 60.01c (24.2%).

4.3 Rank in the top 99% by Liquidity in the Spanish market

DescriptionValueRank
Days untraded in the past quarter14
Ave daily turnoverEUR110 million ($118 million)In top 99%

4.4 Present Value of EUR1000 Invested in the Past [3 Mo, 1 Yr, 3 Yrs]; The Best Periods with PVEUR1000 > 1,115

PVEUR1,0003 mo ago1 yr ago3 yrs ago
SAN.MAEUR1,116EUR1,510EUR1,631
Banks companyEUR1,008EUR1,259EUR1,392
IBEX 35 IndexEUR1,053EUR1,154EUR1,192

4.5 The Best Periods [3 Mo, 1 Yr, 3 Yrs] with Price Change % > 9.2

3-Year price change of 44.2% for Banco Santander outperformed the change of 19.1% in the IBEX35 Index for a relative price change of 25.1%.

Price Change %QuarterYear3 Years
Banco Santander9.344.444.2
Banks company0.825.939.5
IBEX35 Index2.415.419.1

4.6 MCap: 5-Year Increase of EUR11 B [$12B] (17%)

In the past 5 years Market Capitalization has increased by EUR11.1 billion (17%) from EUR64.2 billion to EUR75.3 billion. Based on a dynamic start date of 5 years ago, there have been declines in MCap in 2 out of 5 years.

PriceMCap (EUR B)MCap ($ B)
LastEUR4.4175.380.5
1 Year agoEUR3.0554.559.7
2 Years agoEUR2.4144.846.7
3 Years agoEUR3.0657.269.2
4 Years agoEUR1.1136.741.5
5 Years agoEUR1.9464.272.4

4.7 Created Market Value [CMV] past 4 yrs of EUR5 billion ($5.3 billion)

- Market Capitalization has increased by EUR38.6 billion from EUR36.7 billion to EUR75.3 billion in the last 4 years. This increase comprises cumulative retained earnings (RETE) of EUR33.6 billion and Created Market Value of EUR5 billion. The Created Market Value multiple, defined by the change in MCap for every EUR1 of retained earnings is EUR1.15.

4.8 Annualised Period-based Total Shareholder Returns [TSR %]: The Best Periods with TSR > 7.7%

TSR %1 yr3 yrs5 yrs10 yrs
SAN.MA5117.522.37.8

4.9 P/E/G < 1

The price earnings ratio of 8.2 divided by trailing twelve months eps growth of 22.7% corresponds to an attractive P/E/G of 0.4 times; being less than the value benchmark of 1.0.

EPS Growth (%)22.73
P/E/G0.36
P/E8.17

4.10 Increased VWAP, up 144% in 5 years

In the past five years Volume Weighted Average Price (VWAP) has increased by 143.7% to EUR3.75. Based on a dynamic start date of five years ago, there have been declines in VWAP in 2 out of 5 years.

Past five years, 12 months ended Jun 17 (EUR)

YearHigh PriceVWAPLow Price
20244.933.752.88
20233.642.762.13
20223.142.742.25
20213.121.50.75
20202.081.540.89

4.11 Satisfies one criterion of Benjamin Graham

- The P/E of 8.2 multiplied by the P/NTA of 0.9 is 7.8. Being less than the Benjamin Graham benchmark of 22.5 the stock appears undervalued.

SECTION 5 TODAY'S BEARISH SIGNALS

5.1 3-DAY: STRONG MOMENTUM DOWN

SAN declines 4.1% on robust volume 1.8 times average. Compared with the IBEX 35 Index which fell 285.9 points (or 2.5%) in the 3-days, the relative price change was -1.6%.

The price ranged between a high of EUR4.41 on Monday Jun 17 and a low of EUR4.38 on Friday Jun 14.

JunBanco SantanderClose [EUR]Change %Comment
Mon 17Increases after finding support4.410.7Top Rise
Fri 14Offers earnings yield of 12.3%4.38-0.5VI*=2.3
Thu 13Offers dividend yield of 4.1%4.4-4.3Steepest Fall; VI*=2.1

* RPC - Relative Price Change is % price change of stock less % change of the IBEX35 Index.

[Volume Index (VI); 1 is average]

5.2 Rank in the bottom 14% by Price Performance in the Spanish market

DescriptionValueRank
1-month Price Change %-7.4In Bottom 14%
1-week Price Change %-6.4In Bottom 7%

5.3 Downtrend

Past Month:

- Falls to Rises: In the past month the number of falls outnumbered rises 11:7 or 1.6:1.

5.4 Other Bearish Signals

- Net profit margin has averaged 8.0% in the last 3 years. This is lower than the sector average of 28.5% and suggests a low margin of safety.

SECTION 6 ONGOING BEARISH PARAMETERS

6.1 Declining Volume, down 46% in 5 years

In the past five years, Average Daily Volume of Trading (ADVT) has decreased 45.5% to 30.2 million shares.

Avg. Daily Volume Traded 12 months ended Jun 17, million shares

YearADVT
202430.2
202338.6
202236.6
202151.5
202055.5

6.2 Declining share turnover, down 31% in 5 years

In the past five years, average daily share turnover has decreased 30.7% to EUR105.9 million ($113.2 million). This suggests decreased liquidity.

Past five years, 12 months ended Jun 17 (EUR million)

YearAverage Daily Turnover
2024105.9
2023108.7
2022103.3
2021112.9
2020152.8

6.3 Satisfies 4 out of 9 criteria of Joseph Piotroski [pass mark 5]:

- Positive net income.

- Positive operating cashflow.

- Good quality of earnings [operating cashflow exceeds net income].

- Improvement in asset turnover [growth in revenue of 12.3% exceeded growth in assets of 8.7%].

But does not meet the following 5 criteria of Joseph Piotroski:

- Return on Assets improvement.

- Improvement in long-term debt to total assets.

- Improvement in current ratio.

- Total shares on issue unchanged (or reduction in total shares on issue).

- Improvement in gross margin.

SECTION 7 CORPORATE PROFILE

7.1 Activities

Banco Santander SA. (the Bank) is a financial group that offers a range of financial products. It is Spain's largest Banks sector company by market capitalisation.

7.2 Contact Details

Websitehttp://www.gruposantander.com
Physical AddressCiudad Grupo Santander Boadilla del Monte Madrid, 28660 Spain

7.3 Industry & Sector [of 100 stocks]

Classification LevelName of Sector
Business SectorBanking & Investment Services
Industry GroupBanking Services
IndustryBanks
Economic SectorFinancials

SECTION 8 BANK METRICS

8.1 Bank Metrics (FY2022)

All values are in EUR billion

DescriptionFY2022FY2021Change
Interest Income71.4 46.5 Up 53.7%
Interest Expense32.8 13.1 Up 150.6%
Net Interest Income38.6 33.4 Up 15.7%
Provision1.9 2.8 Down 33.2%
Bank Other Revenue1.5 2.3 Down 33%

Favourable Changes:

- Interest Income up 53.7% from EUR46.5b to EUR71.4b

- Net Interest Income up 15.7% from EUR33.4b to EUR38.6b

- Provision down 33.2% from EUR2.8b to EUR1.9b

Unfavourable Changes:

- Interest Expense up 150.6% from EUR13.1b to EUR32.8b

- Bank Other Revenue down 33% from EUR2.3b to EUR1.5b

SECTION 9 DIVIDEND

9.1 Dividend History

In the past 5 years annual dividends have increased by 8.5c from 9.6c to 18.1c. Based on a start date of 5 years ago, there has been one decline in dividends over the last 5 years.

Date PaidValue (c)Type
29 Apr 202410Interim
31 Oct 20238.1Interim
Tr 12 Months18.1
2022 - 202311.78
2021 - 202210
2020 - 20212.75
2019 - 20209.58

SECTION 10 TOP MANAGEMENT AND BOARD OF DIRECTORS

10.1 Top Management

Top Management [Five top executives with tenure > 5 yrs]

NameDesignationSince Appointment
Jose Antonio AlvarezChief Executive Officer5 Yrs, 5 Mos
Juan Rodriguez InciarteExecutive Director-
Ana Patricia BotinExecutive Director-
Matias Rodriguez InciarteExecutive Director-
Ana Patricia Botin-Sanz de Sautuola y O'SheaExecutive Director-

10.2 Board Of Directors

Board Of Directors [Four directors with tenure < 3 yrs]

NameDesignationSince Appointment
Emile VoestIndependent Director2 Yrs, 3 Mos
Antoine YverIndependent Director2 Yrs, 3 Mos
Carole FerrandIndependent Director2 Yrs, 3 Mos
Homaira AkbariNon-Executive Independent Director-

APPENDIX I DATA & ARCHIVE DOWNLOAD CENTER

SAN: EXPORT DATA TO EXCEL:

+ PRICE VOLUME - 5-YEAR HISTORY

+ PEER COMPARISON

SAN: OTHER INFORMATION:

+ NEWS ARCHIVES - SAN PAST 4 YEARS:

+ PRICE VOLUME CHARTS

+ USD vs EUR EXCHANGE RATE CHARTS IN HTML

+ BOARD OF DIRECTORS

APPENDIX II STOCK IDENTIFIERS

ISIN: ES0113900J37

PermID: 8589934205

CUSIP: E19790109

RIC: SAN.MC

LEI: 5493006QMFDDMYWIAM13

GLOSSARY

ADVT: Average Daily Volume of shares Traded

Annual Return: Dividends Paid In a 12-Month Period/Price at the Beginning of the Period + Capital Gain or Loss over 1 Year/Price 1 Year Ago (%)

Current Ratio: Current Assets/Current Liabilities (times)

Dividend Yield: Dividend Per Share/Share Price (%)

Earnings Yield: Earnings Per Share/Share Price (%)

Income during the n years (3/2/1): Dividends received during the Period

Moving Average Price (n periods): Sum of Prices for each Period/Number of Periods

PV1000: Present value of 1000 invested 1 year/'n' years ago

Price Close/Moving Avg Price: Latest Price/Moving Average Price

Price/Earnings: Share Price/Earnings Per Share (times)

Price/NTA: Closing Share Price/Net Tangible Assets Per Share (times)

Relative Price Change [RPC]: Relative price change is price change of stock with respect to Benchmark Index

Relative Strength (6 Months): Price close today/Price close 6 months ago, then ranked by percentile within the entire market.

Return on Assets: Net Profit/Total Assets (%)

Return on Equity (Shareholders' Funds): Net Profit/Net Assets (%)

TSR: Total Shareholder Returns is expressed as an annualized rate of return for shareholders after allowing for capital appreciation and dividend

TTM: Trailing 12 Months

Volume Index (VI): Number of shares traded in the period/Average number of shares traded for the period

Volume Weighted Average Price (VWAP): The Volume Weighted Average Price (VWAP) is the summation of turnover divided by total volume in the same period.

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data and analysis from Jupiter International (Australia) Pty Ltd trading as BuySellSignals (AFS Licence 222756), who provide round the clock analysis on every stock, every sector, every market, every day. BuySellSignals is not a broker, and does not have executing, corporate advisory or investment banking functions. Jupiter International (Australia) Pty Ltd, its directors, employees and contractors do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate.

Data for the BuySellSignals algorithms is drawn from annual reports, company websites and similar sources of publicly available data. It should be used as a guide only.

Created by www.buysellsignals.com